Cronos to acquire CanAdelaar for €57.5m.

Cronos, a global cannabinoid company, agreed to acquire CanAdelaar, a cannabis company operating within the Netherlands’ adult-use cannabis pilot program, for €57.5m. “Our acquisition of CanAdelaar is a financially compelling and highly strategic transaction that will establish a strategic footprint in Europe and enable us to leverage our investments in borderless products,” Mike Gorenstein, Cronos Chairman, President and CEO.